Monoclonal movements

LONDON—Global Healthcare Opportunities (GHO Capital Partners LLP), a European specialist investor in healthcare, early this year announced its investment to partner with the founding management team in FairJourney Biologics, a provider of antibody discovery services to global biopharma.

Established in 2012 in Porto, Portugal, FairJourney provides outsourced antibody discovery, engineering, production and characterization services to deliver a critical step in the biologics drug discovery value chain for small and mid-sized biopharma.

In partnership with founding management, GHO will provide further capital, sector expertise and international network to build on FairJourney’s unique market position and create a scaled global leader in outsourced biologics discovery and development services. The company will look to expand its footprint, capacity and service capabilities through both organic and inorganic opportunities to accelerate and deliver the next stage of growth.

“We have chosen to partner with GHO not only for our shared vision, but also our common values. With their recent track record of creating transatlantic leaders in the outsourced services space, significant global network and expertise in biologics we can take our proven business model to a new scale,” said Antonio Parada, CEO of FairJourney. “We will deliver more services and capacity to our growing global client base with a continued focus on the quality, flexibility and speed of our service delivery.”

Added the partners at GHO Capital: “This investment in FairJourney is the result of several years’ work by our team to identify market-leading platforms with outstanding management in the biologics space. FairJourney have developed a differentiated proposition with a standout reputation for quality and customer service. With our investment and specialist expertise, Antonio, Maria and the team are well placed to realize our shared ambition for FairJourney to become a global leader in the outsourced discovery and development of biologics.”